ArticleCancer immunology, immunotherapy : CII2008
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Electrochemotherapy of Melanoma Cutaneous Metastases in Organ Transplant Recipients: A Systematic Review of Preclinical and Clinical Studies.International journal of molecular sciences · 2023Pooled it
- Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review.Clinical & experimental metastasis · 2022Pooled it
- Article
- Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation toFrontiers in immunology · 2025Article
- Clinical Insights and Future Prospects: A Comprehensive Narrative Review on Immunomodulation Induced by Electrochemotherapy.Current oncology (Toronto, Ont.) · 2024Review
- Article
- Calcium electroporation of esophageal cancer induces gene expression changes: a sub-study of a phase I clinical trial.Journal of cancer research and clinical oncology · 2023Article
- The Diagnosis and Management of Cutaneous Metastases from Melanoma.International journal of molecular sciences · 2023Review
- Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report.Molecular and clinical oncology · 2023Article
- High-Frequency Nanosecond Bleomycin Electrochemotherapy and its Effects on Changes in the Immune System and Survival.Cancers · 2022Article
- Review
- An overview of the irreversible electroporation for the treatment of liver metastases: When to use it.Frontiers in oncology · 2022Review
- Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer.Frontiers in oncology · 2022Review
- Review
- Electrical Stimulation for Immune Modulation in Cancer Treatments.Frontiers in bioengineering and biotechnology · 2021Review
- Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.Frontiers in oncology · 2021Article
- Local Destruction of Tumors and Systemic Immune Effects.Frontiers in oncology · 2021Review
- Article
- Article
- CD4Clinical & experimental metastasis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeElectrochemotherapy (ECT) is an effective local therapy of human cutaneous cancers but has no effect on distant untreated tumors. We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant. METHODS AND
resultsWe first studied the nature of the cellular recruitment and the expression of various toll-like receptors (TLRs) in tumors treated by ECT. We found that ECT induced a massive recruitment of CD11c and CD11b positive cells in the tumors and a strong increase of TLR9 expression. We then tested antitumor effects of the combination: ECT followed by TLR-9 ligands, CpG oligodeoxynucleotides (CpG ODN), in three murine tumor models. We found that this combination triggered both potent local synergistic antitumor effects, on the ipsi-lateral ECT-treated tumor, and more interestingly, a systemic antitumor response on the contra-lateral untreated tumor, in the three models. The systemic protection was T-cell dependent as it was not observed in nude littermates. The combination induced tumor-specific T cell effectors in the tumor-draining lymph nodes and in the spleen which secreted significantly more gamma-interferon upon activation than with ECT or CpG ODN alone.
conclusionsOur data show that ECT and CpG ODN synergize and induce a significant increase of the local effect and a systemic T-dependent antitumor response. Such combination constitutes a potential innovative vaccination strategy using in situ tumor-associated antigens that could eventually be translated into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.